Introduction: Death from sepsis in the intensive care unit (ITU) is frequently preceded by the development of multiple organ failure as a result of uncontrolled inflammation. Treatment with ω-3 has been demonstrated to attenuate the effects of uncontrolled inflammation and may be clinically beneficial. Method: A randomized control trial investigating the effects of parenteral ω-3 was carried out. Consecutive patients diagnosed with sepsis were entered into the study and randomized to receive either parenteral ω-3 or standard medical care only. The primary outcome measure was a reduction in organ dysfunction using the Sequential Organ Failure Assessment (SOFA) score as a surrogate marker. The secondary outcome measures were mortality, length of stay, mean C-reactive protein (CRP), and days free of organ dysfunction/failure. Results: Sixty patients were included in the study. The baseline demographics were matched for the two cohorts. Patients treated with parenteral ω-3 were associated with a significant reduction in new organ dysfunction (Δ-SOFA 2.2 ± 2.2 vs. 1.0 ± 1.5, P = .005 and maximum-SOFA 10.1 ± 4.2 vs. 8.1 ± 3.2, P = .041) and maximum CRP (186.7 ± 78 vs. 141.5 ± 62.6, P = .019). There was no significant reduction in the length of stay between cohorts. Patients treated with ω-3 in the strata of less severe sepsis had a significant reduction in mortality (P = .042). Conclusion: The treatment of critically ill septic patients with parenteral ω-3 is safe. It is associated with a significant reduction in organ dysfunction. It may be associated with a reduction in mortality in patients with less severe sepsis.
VincentJLSakrYSprungCL. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006;34(2):344-353.
2.
HarrisonDAWelchCAEddlestonJM. The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC case mix programme database. Crit Care. 2006;10(2):R42.
3.
LevyMMDellingerRPTownsendSR. The surviving sepsis campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Crit Care Med. 2010;38(2):367-374.
4.
DellingerRPLevyMMCarletJM. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med. 2008;34(1):17-60.
5.
HallTCBilkuDKAl-LeswasDHorstCDennisonAR. The difficulties of clinical trials evaluating therapeutic agents in patients with severe sepsis. Ir J Med Sci. 2012;181(1):1-6.
6.
Lanza-JacobySFlynnJTMillerS. Parenteral supplementation with a fish-oil emulsion prolongs survival and improves rat lymphocyte function during sepsis. Nutrition. 2001;17(2):112-116.
TeoTCSelleckKMWanJM. Long-term feeding with structured lipid composed of medium-chain and N-3 fatty acids ameliorates endotoxic shock in guinea pigs. Metabolism. 1991;40(11):1152-1159.
9.
CalderPC. Use of fish oil in parenteral nutrition: rationale and reality. Proc Nutr Soc. 2006;65(3):264-277.
10.
CalderPC. Hot topics in parenteral nutrition: rationale for using new lipid emulsions in parenteral nutrition and a review of the trials performed in adults. Proc Nutr Soc. 2009;68(3):252-260.
11.
CalderPC. N-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr. 2006;83(6)(suppl):1505S-1519S.
12.
ChapkinRSKimWLuptonJRMcMurrayDN. Dietary docosahexaenoic and eicosapentaenoic acid: emerging mediators of inflammation. Prostaglandins Leukot Essent Fatty Acids. 2009;81(2-3):187-191.
13.
GalliCCalderPC. Effects of fat and fatty acid intake on inflammatory and immune responses: a critical review. Ann Nutr Metab. 2009;55(1-3):123-139.
14.
LiangBWangSYeYJ. Impact of postoperative omega-3 fatty acid–supplemented parenteral nutrition on clinical outcomes and immunomodulations in colorectal cancer patients. World J Gastroenterol. 2008;14(15):2434-2439.
15.
WachtlerPKonigWSenkalMKemenMKollerM. Influence of a total parenteral nutrition enriched with omega-3 fatty acids on leukotriene synthesis of peripheral leukocytes and systemic cytokine levels in patients with major surgery. J Trauma. 1997;42(2):191-198.
ChapkinRSWangNFanYYLuptonJRPriorIA. Docosahexaenoic acid alters the size and distribution of cell surface microdomains. Biochim Biophys Acta. 2008;1778(2):466-471.
18.
LoCJChiuKCFuMLoRHeltonS. Fish oil decreases macrophage tumor necrosis factor gene transcription by altering the NF kappa B activity. J Surg Res. 1999;82(2):216-221.
19.
NovakTEBabcockTAJhoDHHeltonWSEspatNJ. NF-kappa B inhibition by omega-3 fatty acids modulates LPS-stimulated macrophage TNF-alpha transcription. Am J Physiol Lung Cell Mol Physiol. 2003;284(1):L84-L89.
PaulKPLeichsenringMPfistererM. Influence of n-6 and n-3 polyunsaturated fatty acids on the resistance to experimental tuberculosis. Metabolism. 1997;46(6):619-624.
26.
PalmerAJHoCKAjibolaOAvenellA. The role of omega-3 fatty acid supplemented parenteral nutrition in critical illness in adults: a systematic review and meta-analysis. Crit Care Med. 2013;41(1):307-316.
27.
ManzanaresWDhaliwalRJurewitschBStapletonRDJeejeebhoyKNHeylandDK. Parenteral fish oil lipid emulsions in the critically ill: a systematic review and meta-analysis [published online April 22, 2013]. JPEN J Parenter Enteral Nutr.
28.
BernardGRArtigasABrighamKL. The American-European consensus conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149(3, pt 1):818-824.
29.
RiversENguyenBHavstadS. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345(19):1368-1377.
30.
VincentJLMorenoRTakalaJ. The SOFA (Sepsis-Related Organ Failure Assessment) score to describe organ dysfunction/failure: on behalf of the working group on sepsis-related problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707-710.
31.
VosyliusSSipylaiteJIvaskeviciusJ. Sequential Organ Failure Assessment score as the determinant of outcome for patients with severe sepsis. Croat Med J. 2004;45(6):715-720.
32.
MorenoRVincentJLMatosR. The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care: results of a prospective, multicentre study. Working Group on Sepsis Related Problems of the ESICM. Intensive Care Med. 1999;25(7):686-696.
33.
MorenoRSprungCLAnnaneD. Time course of organ failure in patients with septic shock treated with hydrocortisone: results of the Corticus study. Intensive Care Med. 2011;37(11):1765-1772.
34.
Pontes-ArrudaADemicheleSSethASingerP. The use of an inflammation-modulating diet in patients with acute lung injury or acute respiratory distress syndrome: a meta-analysis of outcome data. JPEN J Parenter Enteral Nutr. 2008;32(6):596-605.
35.
CohenMGRossiJSGarbarinoJ. Insights into the inhibition of platelet activation by omega-3 polyunsaturated fatty acids: beyond aspirin and clopidogrel. Thromb Res. 2011;128(4):335-340.
36.
MoriTABeilinLJBurkeVMorrisJRitchieJ. Interactions between dietary fat, fish, and fish oils and their effects on platelet function in men at risk of cardiovascular disease. Arterioscler Thromb Vasc Biol. 1997;17(2):279-286.
37.
KristensenSDIversenAMSchmidtEB. N-3 polyunsaturated fatty acids and coronary thrombosis. Lipids. 2001;36(suppl):S79-S82.
WatsonPDJoyPSNkondeCHessenSEKaralisDG. Comparison of bleeding complications with omega-3 fatty acids + aspirin + clopidogrel–versus–aspirin + clopidogrel in patients with cardiovascular disease. Am J Cardiol. 2009;104(8):1052-1054.
40.
Brun-BuissonCRoudot-ThoravalFGirouEGrenier-SennelierCDurand-ZaleskiI. The costs of septic syndromes in the intensive care unit and influence of hospital-acquired sepsis. Intensive Care Med. 2003;29(9):1464-1471.
41.
FerreiraFLBotaDPBrossAMelotCVincentJL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA. 2001;286(14):1754-1758.
42.
Rangel-HuertaODAguileraCMMesaMDGilA. Omega-3 long-chain polyunsaturated fatty acids supplementation on inflammatory biomakers: a systematic review of randomised clinical trials. Br J Nutr. 2012;107(suppl 2):S159-S170.
43.
BarbosaVMMilesEACalhauCLafuenteECalderPC. Effects of a fish oil containing lipid emulsion on plasma phospholipid fatty acids, inflammatory markers, and clinical outcomes in septic patients: a randomized, controlled clinical trial. Crit Care. 2010;14(1):R5.
44.
MayerKGokorschSFegbeutelC. Parenteral nutrition with fish oil modulates cytokine response in patients with sepsis. Am J Respir Crit Care Med. 2003;167(10):1321-1328.
45.
MayerKFegbeutelCHattarK. Omega-3 vs. omega-6 lipid emulsions exert differential influence on neutrophils in septic shock patients: impact on plasma fatty acids and lipid mediator generation. Intensive Care Med. 2003;29(9):1472-1481.
46.
SungurtekinHDegirmenciSSungurtekinUOguzBESabirNKaptanogluB. Comparison of the effects of different intravenous fat emulsions in patients with systemic inflammatory response syndrome and sepsis. Nutr Clin Pract. 2011;26(6):665-671.
47.
FrieseckeSLotzeCKohlerJHeinrichAFelixSBAbelP. Fish oil supplementation in the parenteral nutrition of critically ill medical patients: a randomised controlled trial. Intensive Care Med. 2008;34(8):1411-1420.
48.
KhorBSLiawSJShihHCWangLS. Randomized, double blind, placebo-controlled trial of fish-oil-based lipid emulsion infusion for treatment of critically ill patients with severe sepsis. Asian J Surg. 2011;34(1):1-10.
49.
Grau-CarmonaTMoran-GarciaVGarcia-de-LorenzoA. Effect of an enteral diet enriched with eicosapentaenoic acid, gamma-linolenic acid and anti-oxidants on the outcome of mechanically ventilated, critically ill, septic patients. Clin Nutr. 2011;30(5):578-584.
50.
Pontes-ArrudaAMartinsLFde LimaSM. Enteral nutrition with eicosapentaenoic acid, gamma-linolenic acid and antioxidants in the early treatment of sepsis: results from a multicenter, prospective, randomized, double-blinded, controlled study: the INTERSEPT study. Crit Care. 2011;15(3):R144.
51.
Pontes-ArrudaAAragaoAMAlbuquerqueJD. Effects of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock. Crit Care Med. 2006;34(9):2325-2333.
52.
BowdenRGWilsonRLDeikeEGentileM. Fish oil supplementation lowers C-reactive protein levels independent of triglyceride reduction in patients with end-stage renal disease. Nutr Clin Pract. 2009;24(4):508-512.
53.
WohlmuthCDunserMWWurzingerB. Early fish oil supplementation and organ failure in patients with septic shock from abdominal infections: a propensity-matched cohort study. JPEN J Parenter Enteral Nutr. 2010;34(4):431-437.
54.
Kris-EthertonPMHarrisWSAppelLJ; Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2003;23(2):e20-e30.
55.
Perunicic-PekovicGBRasicZRPljesaSI. Effect of n-3 fatty acids on nutritional status and inflammatory markers in haemodialysis patients. Nephrology (Carlton). 2007;12(4):331-336.
56.
MarikPEZalogaGP. Immunonutrition in critically ill patients: a systematic review and analysis of the literature. Intensive Care Med. 2008;34(11):1980-1990.
57.
MarikPEZalogaGP. Immunonutrition in high-risk surgical patients: a systematic review and analysis of the literature. JPEN J Parenter Enteral Nutr. 2010;34(4):378-386.
58.
HeylandDKDhaliwalRDroverJWGramlichLDodekP; Canadian Critical Care Clinical Practice Guidelines Committee. Canadian clinical practice guidelines for nutrition support in mechanically ventilated, critically ill adult patients. JPEN J Parenter Enteral Nutr. 2003;27(5):355-373.
59.
RiceTWWheelerAPThompsonBT. Enteral omega-3 fatty acid, gamma-linolenic acid, and antioxidant supplementation in acute lung injury. JAMA. 2011;306(14):1574-1581.
60.
HellerARRosslerSLitzRJ. Omega-3 fatty acids improve the diagnosis-related clinical outcome. Crit Care Med. 2006;34(4):972-979.
61.
HellerARMayerKHeylandDK. Fish oil in sepsis: if you want to catch more fish, use more hooks. JPEN J Parenter Enteral Nutr. 2011;35(2):154-157.
62.
SuchnerUKatzDPFurstP. Effects of intravenous fat emulsions on lung function in patients with acute respiratory distress syndrome or sepsis. Crit Care Med. 2001;29(8):1569-1574.
63.
LekkaMELiokatisSNathanailCGalaniVNakosG. The impact of intravenous fat emulsion administration in acute lung injury. Am J Respir Crit Care Med. 2004;169(5):638-644.
64.
BurrMLFehilyAMGilbertJF. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and Reinfarction Trial (DART). Lancet. 1989;2(8666):757-761.
65.
SiscovickDSRaghunathanTEKingI. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA. 1995;274(17):1363-1367.
66.
MozaffarianDLemaitreRNKullerLH. Cardiac benefits of fish consumption may depend on the type of fish meal consumed: the Cardiovascular Health Study. Circulation. 2003;107(10):1372-1377.
67.
Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-prevenzione trial. Gruppo Italiano per Lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet. 1999;354(9177):447-455.
68.
KotwalSJunMSullivanDPerkovicVNealB. Omega 3 fatty acids and cardiovascular outcomes: systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2012;5(6):808-818.
69.
LondonBAlbertCAndersonME. Omega-3 fatty acids and cardiac arrhythmias: prior studies and recommendations for future research: a report from the National Heart, Lung, and Blood Institute and Office of Dietary Supplements Omega-3 Fatty Acids and Their Role in Cardiac Arrhythmogenesis Workshop. Circulation. 2007;116(10):e320-e335.
70.
LeafAKangJXXiaoYFBillmanGE. Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. Circulation. 2003;107(21):2646-2652.
71.
de KruifMDLemaireLCGiebelenIA. Prednisolone dose-dependently influences inflammation and coagulation during human endotoxemia. J Immunol. 2007;178(3):1845-1851.
72.
AnnaneDBellissantEBollaertPE. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA. 2009;301(22):2362-2375.
73.
PluessTTHayozDBergerMM. Intravenous fish oil blunts the physiological response to endotoxin in healthy subjects. Intensive Care Med. 2007;33(5):789-797.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
